News

UCB: Positive phase III results
Enlarge image

BusinessBelgium

UCB: Positive phase III results

18.04.2012 - UCBs Cimzia has succeeded in a phase III. That raises hope that the TNF-α inhibitor could gain additional sales in the highly competitive anti-inflammation market.

Brussels –  The TNF alpha inhibitor has met the primary endpoint in a phase III trial to treat adult onset of active axial spondoyloarthritis (AXSA). The study enrolled 325 patients with AXSA who were assigned to treatment with one of two doses of Cimzia (certolizumab pegol) or placebo over a 24-week period. The trial has shown a 20 per cent improvement in the Assessment of Spondyloarthritis International Society (ASAS20) response at week 12 compared to placebo. UCB expects to file for approval in this indication later this year. The pegylated humanised antibody fragment Cimzia (certolizumab pegol) is already approved in Europe and the US for rheumatoid arthritis and in the US for Crohn's disease, although the EU rejected UCB's application to market the drug in the latter indication in 2008. It is UCB's second-biggest product with sales of €312m last year, up more than 50 per cent compared to 2010. Axial spondyloarthritis is a collective name for a series of inflammatory rheumatic diseases of the spine, joints, ligaments and tendons, and includes a spinal condition known as ankylosing spondylitis. Expanding the labelling for Cimzia in this indication is important for UCB to make headway against the drug's rivals in the competitive anti-TNF alpha sectorlike Enbrel (Amgen, Pfizer and others), Humira (Abbott, Eisai ) and Johnson & Johnson's Remicade. The competitors fear the appearance of biosimilar rivals entering the market after the drug's patent expiry in 2014. In addition to the axial spondyloarthritis indications, UCB is also planning to submit Cimzia for psoriatic arthritis by the end of the year, and is also awaiting approval of the drug for rheumatoid arthritis in Japan, where it has been co-developed by Astellas Pharma. 

http://www.european-biotechnology-news.com/news/news/2012-02/positive-phase-iii-results-support-cimzia-label-expansion.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.75 EUR16.67%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%
  • RENEURON (UK)3.15 GBP5.00%

FLOP

  • VECTURA (UK)148.80 GBP-4.25%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • BONE THERAPEUTICS SA (B)16.05 EUR-3.31%

TOP

  • PROTHENA PLC (IE)52.22 USD47.2%
  • FLAMEL TECHNOLOGIES (F)12.58 USD33.1%
  • DBV TECHNOLOGIES (F)64.40 EUR26.3%

FLOP

  • MOLOGEN (D)1.75 EUR-30.0%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.62 GBP-19.5%

TOP

  • KARO BIO (S)29.80 SEK1774.2%
  • NICOX (F)11.20 EUR474.4%
  • SAREUM HOLDINGS (UK)0.62 GBP158.3%

FLOP

  • BB BIOTECH (D)45.00 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.72 SEK-78.9%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 25.07.2016